Compare iShares China Large-Cap ETF (FXI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Smith & Nephew plc — how do they compare? iShares China Large-Cap ETF trades at $34.21 (market cap $3.86B), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.9× iShares China Large-Cap ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Smith & Nephew plc for 120 Days on average.
| FXI | SNN | |
|---|---|---|
Market Cap | $3.86B | $11.10B |
Volume | 16,323,837 | 1,051,703 |
52-Week High | $41.08 | $37.17 |
52-Week Low | $31.59 | $26.42 |
Typical Hold Time | 149 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI (iShares China Large-Cap ETF) trades at $34.30, up 2.63% on the day, but technical indicators signal a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges and geopolitical tensions, though some analysts highlight its attractive valuation at half the S&P 500's P/E ratio. Recent news focuses on U.S.-China relations and export dynamics.
The outlook remains cautious due to China's industrial overcapacity and weak domestic consumption. While valuation appears compelling, political risks and technical weakness suggest limited near-term upside. Investors should weigh the discount against ongoing macroeconomic pressures in China.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
